GlassScriptPhysician profile
Yeo Jin Moon
NPI 1285169474
$6,292.65
in general payments reported to CMS, 2019-2025
47 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $572 · 2022: $2,100 · 2023: $3,306 · 2024: $191 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,220 · Education: $401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,220.14 |
| Education | $400.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $563.15 | 2022-2024 | Calquence, Faslodex, Onglyza |
| Janssen Biotech, INC. | $473.51 | 2021-2023 | Rybrevant, Darzalex, Imbruvica |
| Seagen INC. | $326.71 | 2021-2023 | Adcetris, Tukysa |
| Eisai INC. | $313.29 | 2022-2023 | |
| Pfizer INC. | $306.26 | 2022-2023 | |
| Glaxosmithkline, LLC. | $296.91 | 2021-2023 | Jemperli, Zejula |
| E.R. Squibb & Sons, L.L.C. | $265.53 | 2022-2023 | Opdivo, Reblozyl |
| Tersera Therapeutics LLC | $238.36 | 2022-2024 | Quzyttir, Zoladex |
| Merck Sharp & Dohme LLC | $232.31 | 2021-2023 | Lynparza, Keytruda, Welireg |
| Macrogenics, INC. | $221.55 | 2022-2023 | |
| Lilly USA, LLC | $212.18 | 2021-2023 | Jaypirca, Verzenio, Retevmo |
| Incyte Corporation | $207.89 | 2021-2024 | Jakafi, Monjuvi |
| Astellas Pharma US INC | $201.77 | 2022-2024 | Padcev, Xospata, Cresemba |
| Amgen INC. | $199.12 | 2022-2023 | Kyprolis, Blincyto, Xgeva |
| Takeda Pharmaceuticals U.S.A., INC. | $188.29 | 2021-2023 | Alunbrig, Vpriv, Ninlaro |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yeo Jin Moon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.